Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immuron ( (IMRN) ) has provided an announcement.
On December 11, 2025, Immuron Limited announced the application for quotation of 1,874,964 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities were issued as a result of the conversion of performance rights under the company’s employee incentive scheme. This move is part of Immuron’s ongoing efforts to enhance its capital structure and provide additional equity incentives to its key management personnel, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (IMRN) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Underperform.
Immuron’s stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company’s negative profitability and cash flow challenges are significant concerns. The technical analysis suggests oversold conditions, but the lack of positive valuation metrics further weighs down the score.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is a biopharmaceutical company based in Australia, primarily focused on developing oral immunotherapeutic products for the treatment of gut-mediated diseases. The company is known for its research and development efforts in the field of immunotherapy, targeting both local and systemic immune responses.
Average Trading Volume: 563,790
Technical Sentiment Signal: Sell
Current Market Cap: $8.41M
Learn more about IMRN stock on TipRanks’ Stock Analysis page.